Intellipharmaceutics International Inc. (IPCI)

[numbersarefun]

Odidis are only ones that develop controlled-release products. In annual reports, it says "Drs. Isa and Amina Odidi are our only employees with the knowledge and experience necessary for us to continue development of controlled-release products."

IPCI's slow pipeline is probably the result of the dependency on the Odidis. Intellipharmaceutics has been in business since 1998, and they have not hired or allowed any other scientist to develop anything. All the patents are in the Odidi's name. IPCI has also not developed any immediate-release drugs. Slow pipeline is probably why IPCI is not worth hundreds of millions dollars like other generic drug companies of the same age.

ImpactTrader 16 wrote: "PIPELINE - Very impressive to say the least."